SCHEMBL3774359

SCHEMBL3774359

COc1cc(N2CCN(CC(=O)N3CCN(C4CCCC4)CC3)CC2)ccc1Br

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 6/20 0.46
ALDH1A1 P00352 4/20 0.44
TSHR P16473 2/20 0.44
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.43
GFER P55789 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CTSB P07858 1/20 0.43
CTSS P25774 1/20 0.43
CTSK P43235 1/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3768852 0.98 CCR1 (0.46) CCR1ALDH1A1TSHRKMT2AKDM4E
SCHEMBL3772093 0.91 CTSB (0.52) CCR1ALDH1A1TSHRKMT2AKDM4E
SCHEMBL3779384 0.90 CTSB (0.51) CCR1ALDH1A1TSHRKMT2AKDM4E
SCHEMBL3765294 0.89 ALDH1A1 (0.51) CCR1ALDH1A1TSHRKMT2AKDM4E
SCHEMBL3767770 0.88 CCR1 (0.58) CCR1
SCHEMBL3762797 0.87 CCR1 (0.57) CCR1
SCHEMBL14608924 0.87 TRPV6 (0.49) CCR1ALDH1A1TSHRKMT2AKDM4E
SCHEMBL3773688 0.86 CCR1 (0.58) CCR1
SCHEMBL3771135 0.85 CCR1 (0.51) CCR1ALDH1A1TSHRKMT2AKDM4E
SCHEMBL3772213 0.85 HTT (0.46) CCR1ALDH1A1TSHRKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 CCR1 606/4885ALDH1A1 1210/4885TSHR 436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.